Last reviewed · How we verify
[14C]-GSK2269557 IV infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-GSK2269557 IV infusion ([14C]-GSK2269557 IV infusion) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-GSK2269557 IV infusion TARGET | [14C]-GSK2269557 IV infusion | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-GSK2269557 IV infusion CI watch — RSS
- [14C]-GSK2269557 IV infusion CI watch — Atom
- [14C]-GSK2269557 IV infusion CI watch — JSON
- [14C]-GSK2269557 IV infusion alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-GSK2269557 IV infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-gsk2269557-iv-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab